Monday, July 29, 2013
Thursday, July 25, 2013
Wednesday, July 24, 2013
Voluntary Sector Network survey – findings | Voluntary Sector Network | guardian.co.uk
Voluntary Sector Network survey – findings | Voluntary Sector Network | guardian.co.uk:
"Infographic of findings from the latest Guardian Voluntary Sector Network survey
guardian.co.uk, Wednesday 24 July 2013 07.25 BST
Samantha Jones for the Guardian
A survey conducted by the Guardian Voluntary Sector Network revealed charities' concern about the future.
"
'via Blog this'
"Infographic of findings from the latest Guardian Voluntary Sector Network survey
guardian.co.uk, Wednesday 24 July 2013 07.25 BST
Samantha Jones for the Guardian
A survey conducted by the Guardian Voluntary Sector Network revealed charities' concern about the future.
"
'via Blog this'
Monday, July 22, 2013
FOCP participates in Ramadan and Eid Exhibition - جمعية أصدقاء مرضى السرطان تشارك في معرض رمضان والعيد
Friends of Cancer Patients (FOCP) is participating in the
Ramadan and Eid Exhibition at Sharjah Expo Center from 18th July until 10th August at Hall 4. During the Exhibition we will be providing
information about current and future activities of FOCP, and we will be
distributing awareness brochures to the visitors. Our nurses will also be available
at the exhibition to provide advice and increase awareness for early detection
of Breast Cancer, in addition to accepting donations.
AED5 SMS "zakat > 4219" Zakat by Etisalat SMS AED10 SMS "zakat > 4425"
تشارك جمعية أصدقاء مرضى السرطان في معرض رمضان والعيد في مركز إكسبو الشارقة خلال
الفترة من يوم الخميس الموافق 18 يوليو وحتى يوم السبت الموافق ١٠ أغسطس 2013 في قاعة 4، حيث
ستكون المشاركة عبارة عن: التعريف بنشاطات الجمعية الحالية والمستقبلية،
توزيع البروشورات التوعوية لزوار المعرض، تقديم النصائح التوعوية للكشف المبكر عن
مرض سرطان الثدي من قبل ممرضات في ايام مختارة، بالإضافة إلى جمع التبرعات عن طريق
كوبونات التبرع الخاصة بالجمعية.
Photos from the Opening of the Exhibition
صور من إفتتاح المعرض
Labels:
Breast Cancer,
cancer,
FOCP,
Pink Caravan,
Ramadan,
Sharjah,
Sharjah Expo,
السرطان,
سرطان الثدي، الشارقة،
Thursday, July 18, 2013
Friends of Cancer Patients organises Ramadan workshops to raise breast cancer awareness - جمعية أصدقاء مرضى السرطان تُنظم ندوات رمضانية لزيادة الوعي بسرطان الثدي
The Friends of Cancer Patients charitable
society (FOCP), through its Pink Caravan breast cancer awareness campaign, has
organised workshops for both men and women in the holy month of Ramadan in a bid
to raise breast cancer awareness, and disseminate information about the cancer,
its risk factors, and the role of self examination and early diagnosis.
تنظم جمعية أصدقاء مرضى السرطان، ومن خلال حملة
القافلة الوردية، مبادرتها الرائدة لنشر الوعي حول سرطان الثدي، ورش عمل للرجال
والسيدات خلال شهر رمضان المبارك، في محاولة لرفع مستوى الوعي بمرض سرطان الثدي،
ونشر المعلومات حول المرض، وأعراضه، ودور الفحص الذاتي والتشخيص المبكر في الوقاية
منه.
The workshops are being conducted at Al Multaqa
Ramadan Forum titled 'Breeze of Mercy' at the Zabeel Hall, Dubai World Trade
Centre, from July 12th to 23rd between Fridays and Tuesdays.
It is the cancer society's second consecutive year of participation at the huge Ramadan event which is organised annually by the Department of Tourism and Commerce Marketing.
It is the cancer society's second consecutive year of participation at the huge Ramadan event which is organised annually by the Department of Tourism and Commerce Marketing.
وتقام الندوات خلال إنعقاد
الملتقى الرمضاني تحت عنوان "نسائم الرحمة" في قاعة زعبيل بمركز دبي
التجاري العالمي من 12 وحتى 23 يوليو ما بين أيام الجمعة والثلاثاء. وتشارك جمعية
أصدقاء مرضى السرطان للعام الثاني على التوالي في هذه الفعالية الرمضانية الكبيرة
التي تُقام سنويا بتنظيم دائرة السياحة والتسويق التجاري بدبي.
Photos from the event - صور من الفعالية
Tuesday, July 16, 2013
حقائق ومعلومات يجب أن تعرفها عن سرطان الثدي
سرطان الثدي هو نوع من السرطان
(المرض الخبيث) الذي يؤثر على النساء والرجال ولكن بنسب أعلى للنساء، وقد تبين أن
28٪ من مجموع حالات السرطان في جميع أنحاء العالم هي حالات لسرطان الثدي.
سرطان الثدي هو ثاني أكبر سبب
لوفيات السرطان بعد سرطان الرئة.
يحدث اصابة بسرطان الثدي بمعدل
1 من أصل 8 نساء خلال فترات حياتهن.
8 من أصل 10 من
أورام الثدي تكون غير سرطانية.
9.5من أصل 10 نساء
تم علاجهن من سرطان الثدي في وقت مبكر بحيث يتمتعن بحياة طبيعية خلال 5 سنوات.
لا يمكن منع سرطان الثدي ولكن يمكن
علاجه والشفاء منه إذا اكتُشف في وقت مبكر.
يعتبر الكشف المبكر وتحديد المرض في
بدايته من أهم وسائل مكافحة سرطان الثدي.
من هم الأكثر
عرضه لسرطان الثدي؟
من هم فوق سن ال 50 عاما.
من كان لها أم أو أخت أو ابنة أصيبت
بسرطان الثدي (تاريخ عائلي لسرطان الثدي).
من أنجبت طفلها الأول بعد سن 35
عاما.
من بدأت دورتها الشهرية قبل سن 12
عاما.
من تأخر عندها سن اليأس.
من أصيب بالسرطان من قبل.
من تتناول وجبات عالية الدهون
ويعاني من 40٪ أو أكثر فوق الوزن.
من يدخن أكثر من 10 سجائر يوميا.
من يشرب الكحول بشكل منتظم.
من يستخدم “العلاج بالهرمونات
البديلة” أو “الحبوب” لفترة طويلة.
سرطان الثدي يمكن أن يؤثر على أي
امرأة حتى لو انها لا تعاني من أي من عوامل الخطر المذكورة.
هل أنت في خطر
حقيقي؟
ماذا يمكنك أن
تفعل؟
الفحص الذاتي للثدي بانتظام.
فحص طبي منتظم من قبل الطبيب.
فحص الثدي بالأشعة السينية بعد سن
ال 40 عاما.
تقليل خطر الاصابة بسرطان الثدي (عن
طريق الحفاظ على وزن صحي وتناول الطعام الصحي والتوقف عن التدخين وممارسة الرياضة).
متي يجب القيام
بالفحص السريري على يد أحد الأطباء؟
يتم ذلك كجزء من الفحص الصحي السنوي
أو عند الشعور بوجود أي شئ غير طبيعي.
عدد مرات الفحص:
بدءً من سن ال 20 سنة : ينبغي
القيام بالفحص الطبي كل 3 سنوات.
بعد سن ال 40 سنة : ينبغي القيام
بالفحص الطبي مرة كل عام.
متى يتم استخدام الفحص بالأشعة
السينية؟
فحص الثدي بالأشعة السينية هو تقنية
تقوم على فحص الثدي باستخدام الأشعة للوصول الى أي تغيير غير طبيعي حتى قبل أن يتم
اكتشافه من قبل النساء أنفسهن أو من قبل الطبيب.
متى يتم الفحص:
من سن 40 عاما فما يتم اجراء الفحص
مرة كل سنة إلى سنتين.
من سن 35 سنة إذا كان هناك تاريخ
عائلي إيجابي للإصابة بسرطان الثدي.
توقيت الفحص
باستخدام الأشعة السينية:
ويمكن أن يتم الفحص في أي وقت ولكن
يفضل أن يكون ذلك بعد بدء دورة الطمث (في الأيام ال 10 الأولى من فترة).
قبل الذهاب إلى
موعد فحص الثدي
لا تستخدمي التطيب أو العطر أو مزيل
العرق أو البودرة لأنها تؤثر على نتيجة الفحص.
أحضري معك تقاريرالفحص بالأشعة
القديمة ان وجدت.
فحص الثدي بالأشعة السينية هو
الأسلوب الوحيد الذي أثبت فعاليته في التقليل من وفيات سرطان الثدي من 20 إلى 30٪
في النساء البالغات أكثر من 50 سنة من العمر.
Sunday, July 14, 2013
Exclusive: Cancer - A cure just got closer thanks to a tiny British company - and the result could change lives of millions - Science - News - The Independent
A revolution is brewing on an English business park as scientists harness our natural-born killers – the T cells – to target malign tumours
1 / 2
Related articles
A single-storey workshop on a nondescript business park in Oxfordshire is not the sort of place where you would expect scientific revolutions to take place. But behind the white-painted walls of this small start-up company, scientists are talking about the impossible – a potential cure for cancer.
For the past 20 years, the former academics who set up Immunocore have worked hard on realising their dream of developing a totally new approach to cancer treatment, and finally it looks as if their endeavours are beginning to pay off. In the past three weeks, the company has signed contracts with two of the biggest players in the pharmaceuticals industry which could lead to hundreds of millions of pounds flowing into the firm's unique research on cancer immunotherapy – using the body's own immune system to fight tumour cells.
Immunocore is probably the only company in the world that has developed a way of harnessing the power of the immune system's natural-born killer cells: the T-cells of the blood which nature has designed over millions of years of evolution to seek out and kill invading pathogens, such as viruses and bacteria. T-cells are not nearly as good at finding and killing cancer cells, but the hard-nosed executives of the drugs industry – who are notoriously cautious when it comes to investments – believe Immunocore may have found a way around this so that cancer patients in future are able to fend off their disease with their own immune defences.
"Immunotherapy is radically different," said Bent Jakobsen, the Danish-born chief scientific officer of Immunocore who started to study T-cells 20 years ago while working at the Medical Research Council's Laboratory of Molecular Biology in Cambridge. "It doesn't do away with the other cancer treatments by any means, but it adds something to the arsenal that has one unique feature – it may have the potency to actually cure cancer," Dr Jakobsen said.
It is this potency that has attracted the attention of Genentech in California, owned by the Swiss giant Roche, and Britain's GlaxoSmithKline. Both companies have independently signed deals with Immunocore that could result in up to half a billion pounds being invested in new cancer treatments based on its unique T-cell therapy.
It is no understatement to say that cancer immunotherapy, or immuno-oncology as it is technically called, represents a sea change in terms of cancer treatment. Cancer in the past has been largely treated by slicing (surgery), poisoning (chemotherapy) or burning (radiotherapy). All are burdened with the inherent problem of how to spare healthy tissue from irreparable damage while ensuring that every cancer cell is killed, deactivated or removed.
Now there is another approach based on the immune system, a complex web of cells, tissues and organs that constantly strive to keep the body free of disease, which almost certainly includes keeping cancerous cells in check.
For many years, scientists have realised that the immune system plays a key role in cancer prevention. There is ample evidence of this, not least from patients who are immune-suppressed in some way – they are more likely than other patients to develop cancer.
The immune system has two basic ways of fighting invading pathogens and the body's own cells that have gone awry. One involves the release of free-floating proteins, or antibodies, that lock on to an invader, triggering other immune cells to come in and sweep them away.
Many organisations have tried to develop anti-cancer treatments based on antibodies, with limited success, Dr Jakobsen said. Part of the problem is that antibodies are not really designed to recognise cells. What Immunocore has done is to build a therapy around the second arm of the immune system, known as cellular immunity, where T-cells seek out and destroy invading pathogens.
"There are a lot of companies working with antibodies but we are virtually the only company in the world that has managed to work with T-cells. It has taken 20 years and from that point we are unique," Dr Jakobsen said.
Immunocore has found a way of designing small protein molecules, which it calls ImmTACs, that effectively act as double-ended glue. At one end they stick to cancer cells, strongly and very specifically, leaving healthy cells untouched. At the other end they stick to T-cells.
The technology is based on the "T-cell receptor", the protein that sticks out of the surface of the T-cell and binds to its enemy target. Immunocore's ImmTACs are effectively independent T-cell receptors that are "bispecific", meaning they bind strongly to cancer cells at one end, and T-cells at the other – so introducing cancer cells to their nemesis.
"What we can do is to use that scaffold of the T-cell receptor to make something that is very good at recognising cancer even if it doesn't exist naturally," said Dr Jakobsen. "Although T-cells are not very keen at recognising cancer, we can force them to do so. The potential you have if you can engineer T-cell receptors is quite enormous. You can find any type of cell and any kind of target. This means the approach can in theory be used against any cancer, whether it is tumours of the prostate, breast, liver or the pancreas.
The key to the success of the technique is being able to distinguish between a cancer cell and a normal, healthy cell. Immunocore's drug does this by recognising small proteins or peptides that stick out from the surface membrane of cancer cells. All cells extrude peptides on their membranes and these peptides act like a shop window, telling scientists what is going on within the cell, and whether it is cancerous or not.
"All these little peptides tell you the story of the cell. The forest of them on the cell surface is a sort of display saying 'I am this kind of cell. This is my identity and this is everything going on inside me'," Dr Jakobsen explained.
Immunocore is building up a database of peptide targets on cancer cells in order to design T-cell receptors that can target them, leaving healthy cells alone and so minimising possible side effects – or that is the hope.
The first phase clinical trial of the company's therapy, carried out on a small number of patients in Britain and the United States with advanced melanoma, has shown that people can tolerate the drug reasonably well and preliminary results suggest there are "early signs of anti-tumour activity", the company said.
A danger with deploying T-cells against cancer is their potency. Yet it is this very potency that it is so exciting because it could lead to a cure for metastatic disease that has spread around the body, Dr Jakobsen said. "You can never make a single-mechanism drug that would come anywhere near a T-cell in terms of its potency.
"If you want to make an impact on cancer you need something that is incredibly potent – but when something goes wrong, it goes badly wrong. I think the honest truth about all cancer treatments is that no matter how much we test and do beforehand, it will continue to go wrong sometimes."
One infamous case of something going disastrously wrong was a clinical trial in 2006 at Northwick Park Hospital in London where scientists were testing a powerful immuno-regulatory drug on six volunteers. All suffered serious side effects caused by the overstimulation of their immune systems.
But Dr Jakobsen said the clinical trial of Immunocore's T-cell drug, as well as future trials, are inherently safe because they are based on incremental rises in dose. All indications suggest it will lead to the expected breakthrough.
He added: "All the pharma companies have come to the realisation that immunotherapy may hold the ultimate key to cancer; it is the missing link in cancer treatment that can give cures."
"They have seen this technology develop. It has come over the mountain top, if you like. With our melanoma trial they have seen it is safe – and it is working."
T-cell therapy
Using the body's immune system to fight cancer is one of the most promising areas of therapy, and could prove particularly helpful in the treatment of metastatic disease, when the cancer has spread from its original site.
The immune system is complex and is composed of many kinds of cells, proteins and chemical messengers that modulate how it works. Scientists are working on ways of exploiting the immune defences to recognise and eliminate cells that have become cancerous.
One of the most interesting examples is ipilimumab, a "monoclonal antibody" made by Bristol-Myers-Squib. It recognises and binds to a molecule, called CTLA-4, which is found on the T-cells of the immune system. CTLA-4 normally keeps T-cells from proliferating, but in the presence of ipilimumab, it becomes blocked, allowing T-cells to increase in numbers, so leading them to attack cancer cells.
Other drugs based on monoclonal antibodies are designed to attack tumours more directly. When they bind to a cancerous cell, it serves as a signal for other cells of the immune system to come in and sweep the cancer cells away.
The trouble is that cancer cells are notoriously mutational. Eliminating 99.9 per cent of cancer cells in a patient may be an improvement, but it still leaves 0.1 per cent that could "escape".
One hope of using T-cells, is that this possibility of escape is narrowed down, or even eliminated. Of course, these are still early days. This is only just beginning to go through the first clinical trials. It could take five or 10 years before we know whether or not they work.
Labels:
cancer,
cancer immunotherapy,
cure,
gsk,
immuno-oncology,
immunocore,
malign tumours,
roche,
t-cell therapy
Subscribe to:
Posts (Atom)








